Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
SEC Accession No. 0001213900-17-012392
Filing Date
2017-11-20
Accepted
2017-11-20 17:02:56
Documents
77
Period of Report
2017-06-30

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 1 TO FORM 10-K f10k2017a1_dandritbiotech.htm 10-K/A 700854
2 CERTIFICATION f10k2017a1ex31-1_dandrit.htm EX-31.1 10468
3 CERTIFICATION f10k2017a1ex31-2_dandrit.htm EX-31.2 9452
4 CERTIFICATION f10k2017a1ex32-1_dandrit.htm EX-32.1 3766
5 CERTIFICATION f10k2017a1ex32-2_dandrit.htm EX-32.2 3697
6 GRAPHIC image_001.jpg GRAPHIC 16622
  Complete submission text file 0001213900-17-012392.txt   4450672

Data Files

Seq Description Document Type Size
7 XBRL INSTANCE FILE ddrt-20170630.xml EX-101.INS 672790
8 XBRL SCHEMA FILE ddrt-20170630.xsd EX-101.SCH 53369
9 XBRL CALCULATION FILE ddrt-20170630_cal.xml EX-101.CAL 57715
10 XBRL DEFINITION FILE ddrt-20170630_def.xml EX-101.DEF 193110
11 XBRL LABEL FILE ddrt-20170630_lab.xml EX-101.LAB 486572
12 XBRL PRESENTATION FILE ddrt-20170630_pre.xml EX-101.PRE 346193
Mailing Address STUMPEDYSSEVEJ 17, 2970 H?RSHOLM G7
Business Address STUMPEDYSSEVEJ 17, 2970 H?RSHOLM G7 45 39179840
DanDrit Biotech USA, Inc. (Filer) CIK: 0001527728 (see all company filings)

EIN.: 452259340 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 10-K/A | Act: 34 | File No.: 000-54478 | Film No.: 171214408
SIC: 2834 Pharmaceutical Preparations